NEW clinical trial for healthy volunteers aged 18 to 40. Get paid for your time!

We are carrying out a clinical trial with an investigational drug that is being developed for the treatment of cancer. The study drug intends to stimulate specific functions within the body in order to initiate an immune response to fight cancer, which is a different approach than most cancer drugs. The investigational drug has been shown to have anti-cancer effects in animal models. The results of this study will help us to plan for future clinical trials in patients.

Register your interest in this clinical trial

Study summary

This study will be conducted at our clinical trials unit in London Bridge and will involve healthy male and female volunteers aged 18-40.

You will need to attend a screening appointment within 13 days of admission. If successful, you will be required to be in our unit for 1 in-house stay of 5 days/4 nights. In addition, there will be 3 outpatient visits 5, 6 and 14 days after receiving the drug, as well as a follow up visit 30 days after receiving the drug.

Study dates

Cohort 2c 

  • Screening period: November 30th-December 4th (only 1x screening appointment required)
  • In-house period: December 6th-December 10th
  • Outpatient visits: December 11th, 12th, 21st
  • Follow-up visit: January 6th

Cohort 2d

  • Screening period: November 30th-December 7th (only 1x screening appointment required)
  • In-house period: December 10th-December 14th
  • Outpatient visits: December 15th, 16th, 25th
  • Follow-up visit: January 10th


Who can take part?

To be eligible to take part in this study you must fit the following criteria:

  • Healthy males or females aged between 18 and 40 (inclusive)
  • You must have a Body Mass Index (BMI) within the range 18.0-25.0 kg/m² (inclusive)
  • You must be a non-smoker and must not have used tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g., gum, patch, and electronic cigarettes) within six months prior to admission onto the study
  • You must not test positive hepatitis B/C, HIV, alcohol or drugs or show any evidence of drug or alcohol abuse within the last 12 months. (Alcohol abuse is defined as a regular weekly intake of more than 21 units)
  • You must be healthy with no underlying medical conditions that may either interfere with participation in the clinical study, and/or put you at any significant risk
  • You must not be on any regular medications, including over the counter medications
  • You must not have donated blood within 16 weeks prior to dosing
  • You must not have any history of cancer or autoimmune/antibody-mediated diseases. (For examples rheumatoid arthritis, multiple sclerosis, lupus, autoimmune hepatitis…etc.)
  • You must not be pregnant or breastfeeding
  • Female volunteers of childbearing potential, if heterosexually active, must agree to the use of highly effective contraception starting at least one menstrual cycle before the drug administration and continuing for at least 3 months after the final study drug dose.
  • Male subjects must be willing to use appropriate contraception throughout the study and for three months after the last dose of study medication. They must also agree not to donate sperm for three months following the final administration of the study drug.

A full list of acceptable contraceptive methods will be discussed in full by a member of the recruitment team and a study doctor during screening.

Study payment
In recognition of the time involved in taking part in this study, you will receive £1,008 (£336 bonus and £672 study payment) on completion of the study provided you comply fully with all the study requirements.

Get in touch
Call our team for more information: +44 (0) 20 7042 5800 (opt 1)
We are open weekdays 9am-5pm
or email us: volunteer@richmondpharmacology.com

Register your interest in this clinical trial

Ref: E01 EXC_July 2017 (email_website_advert text)

The contents of this page have been approved by an ethics committee. Any response to this advertisement will be recorded. Your response will not place you under any obligation to participate in this trial.

You may be required to remain resident in the unit until resolution of any safety issues, after which you will be discharged from the unit.